Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 4
2005 5
2006 8
2007 9
2008 6
2009 13
2010 5
2011 14
2012 13
2013 13
2014 7
2015 9
2016 10
2017 15
2018 3
2019 5
2020 12
2021 6
2022 6
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Vanishing Bone Disease.
Suzuki T, Sekine I. Suzuki T, et al. Among authors: sekine i. Intern Med. 2024 Apr 9. doi: 10.2169/internalmedicine.3271-23. Online ahead of print. Intern Med. 2024. PMID: 38599868 Free article. No abstract available.
Immune checkpoint inhibitor-related myocarditis.
Tajiri K, Aonuma K, Sekine I. Tajiri K, et al. Among authors: sekine i. Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12. doi: 10.1093/jjco/hyx154. Jpn J Clin Oncol. 2018. PMID: 29045749 Review.
Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study.
Shukuya T, Takahashi K, Shintani Y, Miura K, Sekine I, Takayama K, Inoue A, Okamoto I, Kiura K, Kawaguchi T, Yamamoto N, Miyaoka E, Yoshino I, Date H. Shukuya T, et al. Among authors: sekine i. J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1274-1285. doi: 10.1002/jcsm.13216. Epub 2023 Mar 10. J Cachexia Sarcopenia Muscle. 2023. PMID: 36905129 Free PMC article.
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.
Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Among authors: sekine i. Int J Clin Oncol. 2023 Aug;28(8):941-955. doi: 10.1007/s10147-023-02360-8. Epub 2023 Jun 10. Int J Clin Oncol. 2023. PMID: 37300720 Free PMC article.
Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K, Aonuma K, Sekine I. Tajiri K, et al. Among authors: sekine i. Jpn J Clin Oncol. 2017 Sep 1;47(9):779-785. doi: 10.1093/jjco/hyx071. Jpn J Clin Oncol. 2017. PMID: 28531278 Free article. Review.
Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
Hoshi A, Bando H, Sekine I. Hoshi A, et al. Among authors: sekine i. N Engl J Med. 2021 Oct 7;385(15):1439-1440. doi: 10.1056/NEJMc2112373. N Engl J Med. 2021. PMID: 34614337 No abstract available.
165 results